205 results about "P. multocida" patented technology

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the glycosaminoglycan synthases from Pasteurella multocida. The methodology of the present invention includes providing an enzymatically active glycosaminoglycan synthase enzyme from Pasteurella multocida, providing a synthetic, artificial acceptor for the glycosaminoglycan synthase enzyme; combining the synthetic, artificial acceptor with the glycosaminoglycan synthase enzyme within a reaction medium, wherein the reaction medium contains at least one sugar precursor selected from the group consisting of UDP-GlcA, UDP-GlcNAc, UDP-GalNAc, and reacting the glycosaminoglycan synthase enzyme with the synthetic, artificial acceptor to produce an oligosaccharide or polysaccharide polymer. The glycosaminoglycan synthase enzyme may be hyaluronan synthase, chondroitin synthase, or heparosan synthase from P. multocida, and the oligosaccharide or polysaccharide polymer may be hyaluronic acid (hyaluronan), chondroitin, heparosan, or combinations thereof.

The invention discloses a combination of primer and probe for rapidly detecting pasteurella multocida on site by RPA-LFD. A forward primer sequence is shown in SEQ ID No. 1; a reverse primer sequence is shown in SEQ ID No. 2; a probe sequence is shown in SEQ ID No. 3. The invention also discloses a kit for detecting pasteurella multocida. The pasteurella multocida RPA-nfo detection combination of primer and probe and kit have high sensitivity and strong specificity, at least can detect six copied / reacted Pasteurella multocida DNAs, and can perform sensitive, specific and rapid detection of Pasteurella multocida DNA on crude lysate of a sample to be detected within 25 min by means of a constant-temperature water bath kettle or human armpit temperature without special instrument and equipment, so as to be suitable for the diagnosis of the pasteurella mutocida disease on site or base.

The invention relates to a veterinary antibacterial drug composition containing lysozyme and oligosaccharide and an application thereof. The composition can be prepared into powder, granules, premixes, suspensions and oral solutions by mixing a pharmaceutically acceptable drug carrier with the main drugs of the lysozyme, the oligosaccharide and an antibacterial drug, as well as the auxiliary ingredients of biotin, phytic acid, trehalose, glycine and the like which are used for coordination, according to a conventional preparation method. The composition not only can enhance the self immunity of animals, equalize the absorption of amino acids and mineral substances in vivo and broaden the antimicrobial spectrum, but also has high efficiency, safety and no toxic and side effect and is not easy to lead to drug tolerance and drug resistance. The composition is used for preventing and treating intestinal diseases and respiratory diseases, such as colibacillosis, salmonellosis, pasteurella multocida, staphylococosis and the like, of livestock and poultry. Meanwhile, the developed drugs can be used for effectively substituting the traditional veterinary antibiotic drugs which are easy to lead to drug tolerance.

The invention relates to a bivalent inactivated vaccine for bovine multocida pasteurellosis, belonging to the technical field of preparation of veterinary biological products. The bivalent inactivatedvaccine provided by the invention is composed of antigens and a vaccine adjuvant, wherein the antigens are a bovine multocida pasteurellosis capsular type-A Pm-TJ strain and a bovine multocida pasteurellosis capsular type-B C45-2 strain. For the bivalent inactivated vaccine prepared by adopting the method provided by the invention, the concentration purifying process is adopted, the fermentationculture process of the bovine multocida pasteurellosis capsular type-B C45-2 strain is optimized, so that the fermentation time is shortened by one half, and the production efficiency is improved. Forthe bivalent inactivated vaccine provided by the invention, the bovine fibrinous and suppurative pneumonia and bovine hemorrhagic septicemia caused by bovine pasteurella multocida infection can be prevented through one-time injection immunization, and the bivalent inactivated vaccine has the features of safety, reliability and good immune effect.

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin / heparosan synthases from Pasteurella multocida, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure.

The present invention relates to: Myoviridae bacteriophage Pas-MUP-1 (accession number KCTC 12706BP) which has the capability to specifically destroy Pasteurella multocida, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Pasteurella multocida infections, using a composition containing bacteriophage Pas-MUP-1 as an active ingredient.

A plasmid, recombinant engineering bacteria and a preparation method of hyaluronic acid with uniform molecular weight belong to the technical field of gene engineering. A first expression plasmid containing a Pasteurella multocida hyaluronan synthase gene (SEQ NO.1 in the sequence table) and a second recombinant expression plasmid containing hyaluronic acid precursor synthesis related genes (SEQ NO.2, SEQ NO.3, SEQ NO.4 and SEQ NO.5 in the sequence table) cloned from Bacillus subtilis are introduced into gram positive safe microorganisms, and an expression regulation and control system consisting of the two recombinant expression plasmids respectively controls hyaluronan synthase and hyaluronic acid precursor synthesis related enzyme, so as to obtain hyaluronic acid with uniform molecular weight by a biosynthesis method. The method provided by the invention not only improves the capability of the host strains to synthesize hyaluronic acid, but also can obtain several varieties of sufficient pure hyaluronic acid with uniform molecular weight.

The invention provides a multiplex PCR (Polymerase Chain Reaction) primer group for avian pathogenic escherichia coli, pasteurella multocida, proteus mirabilis, pseudomonas aeruginosa, salmonella andstaphylococcus aureus, a multiplex PCR detection kit comprising the primer group, and a multiplex PCR detection method using the primer group. The primer group comprises primer pairs PhoA-F and PhoA-Rfor specifically amplifying a gene phoA of the avian escherichia coli, primer pairs KMT-F and KMT-R for specifically amplifying a gene KMT1 of the pasteurella multocida, primer pairs AtpD-F and AtpD-R for specifically amplifying a gene AtpD of the proteus mirabilis, primer pairs PETA-F and PETA-R for specifically amplifying a gene PETA of the pseudomonas aeruginosa, primer pairs InvA-F and InvA-Rfor specifically amplifying a gene InvA of the salmonella, and prier pairs NuC-F and NuC-R for specifically amplifying a gene nuc of the staphylococcus aureus.

The invention provides a swine pasteurellosis bivalent inactivated vaccine, which can prevent infection caused by two different capsule serotypes of pasteurella multocida, reaches the effect that one stitch of vaccine can prevent multiple infections, reduces the cost, does not have the hidden trouble of dispersing toxin and is safe and reliable. The invention also provides a preparation method for the swine pasteurellosis bivalent inactivated vaccine.

The invention relates to bacillus subtilis fermentation broth of a Chinese herbal medicine as well as preparation and an application of the bacillus subtilis fermentation broth. The Chinese herbal medicine refers to Chinese gall; according to pasteurella multocida and staphylococcus aureus inhibiting screening tests, the Chinese gall can inhibit growth of the pasteurella multocida and the staphylococcus aureus, bacillus subtilis AP139 is used for fermenting the Chinese gall, spraying is performed in an animal breeding shed, the fermented Chinese herbal medicine remarkably inhibits the growth of the pasteurella multocida and the staphylococcus aureus in the air, the effect is superior to those of a bacillus subtilis AP139 separate fermentation group and a Chinese herbal medicine control group, and the fermentation broth has the broader application prospect.

The invention discloses a method for manufacturing a vaccine for animals with progressive atrophic rhinitis (PAR), which comprises the following steps that: nucleic acid fragments of polypeptides with three respective amino acid sequences encoded by which are 2-486, 486-986 or 986-1281 amino acid residues corresponding to Pasteurella multocida toxin (PMT) protein are expressed in Escherichia coli in a large amount respectively, and the polypeptides are separated and used for preparing a vaccine which can excite the generation of an antibody against Pasteurella multocida (related to the progressive atrophic rhinitis). The invention also discloses a method for manufacturing a multivalent vaccine capable of at least preventing the PAR for the animals, which comprises the following steps that: the multivalent vaccine is obtained by mixing the three polypeptides for the PAR prepared by the method and at least one pathogenic antigen related with other animal diseases or an epitope thereof.

The invention provides a subunit vaccine immunologic adjuvant and application thereof. The adjuvant is a fusogenic peptide of antibacterial peptide and allanoin tripeptide and has an amino acid sequence of SEQ.ID.NO.1 and a nucleotide sequence of SEQIDNO.2. In the invention, PG-1-GGGGS-3BS fusogenic peptide is used as a molecular adjuvant, and the immunogenicity of the outer membrane protein of chicken pasteurella multocida can be enhanced effectively; when the PG-1-GGGGS-3BS fusogenic peptide is used as a molecular adjuvant, a eukaryotic yeast expression vector is selected, the fusogenic peptide can be expressed and purified easily, can be modified by glycosylation and the like, and is easy for mass production; the fusogenic peptide expressed by yeast has modifier genes of eukaryotic cells, is similar to the structure of PG-1 expression in a mammal body and has good biological activity.

The invention provides a method for extracting lipopolysaccharides from avian pasteurella multocida and preparing a lipopolysaccharide vaccine. The method comprises the following eight steps of: 1, preparing culture solution of avian pasteurella multocida; 2, collecting the avian pasteurella multocida from the culture solution of avian pasteurella multocida; 3, crushing the avian pasteurella multocida by using ultrasonic wave; 4, crudely extracting solution of lipopolysaccharides from the avian pasteurella multocida crushed by the ultrasonic wave; 5, extracting concentrated solution of lipopolysaccharides from the crudely extracted solution of lipopolysaccharides; 6, performing enzymolysis on deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the concentrated solution of lipopolysaccharides by using DNA and RNA enzymes; 7, preparing the purified lipopolysaccharides; and 8, preparing the lipopolysaccharide vaccine of avian pasteurella multocida from the purified lipopolysaccharides. According to animal immunization experiments and animal virus attacking experiments, after the lipopolysaccharide vaccine of avian pasteurella multocida, prepared by the method, is used for immunizing chickens for three times, the immunized chickens can be effectively prevented from suffering from avian pasteurella multocida disease.